FDA Decision Date for ImmunityBio's Anktiva in Papillary Bladder Cancer
FDA White Oak Campus, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, United StatesImmunityBio
已排期日期确定性: 已排期已公布为计划日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已排期”的图钉可信度 75%总体可信度: 75%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 4 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉ImmunityBio's[1][2] release says the FDA "assigned a PDUFA target action date of January 6, 2027" for the supplemental BLA.
The FDA has assigned a 6 January 2027 PDUFA target date for ImmunityBio's supplemental BLA for Anktiva plus BCG in BCG-unresponsive non-muscle invasive bladder cancer with papillary disease.
1.00